Recent Developments in Noninvasive Neuromodulation for Mood and Anxiety Disorders

Yupei P. Hu, Gopalkumar Rakesh, Sarah H. Lisanby

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Noninvasive neuromodulation refers to a family of device-based interventions that apply electrical or magnetic fields, either at convulsive or subconvulsive levels, to the brain through the intact skull to modulate neural function. This is a rapidly evolving field, with new research emerging regarding the various roles that these devices can play both in studying the neural mechanisms underlying mood and anxiety disorders, and in treating pharmacoresistant conditions either on their own or in combination with other therapies. Each neuromodulation modality has its pros and cons and should be carefully chosen after weighing the risks and benefits. This manuscript reviews some of the most exciting developments in this field over the past year and emphasizes themes that are emerging as being important for these tools to fulfill their potential to transform how we study and treat mood and anxiety disorders. Key among these themes is the concept of how we understand the “dose” of the stimulation, and how exogenously applied fields interact with endogenous brain activity. Refining the concept of dose will ultimately be important in allowing clinicians and researchers to apply the procedure with precision to engage the targeted network to achieve the desired effects in each individual. The large parameter space defining dose of neuromodulation makes interpreting the literature on safety and efficacy challenging and highlights the need for clear and accurate reporting of the spatial, temporal, and contextual features of dosage to make the emerging literature base as informative as possible. Ultimately, the impact of noninvasive neuromodulation devices is potentially transformational given their utility in providing mechanistic insight into the circuit-based and oscillatory origins of mood and anxiety disorders, as well as providing therapeutic interventions rationally designed to target disease-related processes.

Original languageEnglish
Pages (from-to)173-185
Number of pages13
JournalCurrent Behavioral Neuroscience Reports
Volume2
Issue number3
DOIs
StatePublished - Sep 1 2015

Bibliographical note

Publisher Copyright:
© 2015, Springer International Publishing AG.

Funding

Dr. Lisanby is supported by grants from NIH (U01 MH084241, R01 MH091083, R01 NS088674), foundations (Brain & Behavior Foundation, Stanley Foundation), and industry (Neosync, Brainsway, NexStim).

FundersFunder number
Brain & Behavior Research Foundation
National Institutes of Health (NIH)U01 MH084241, R01 MH091083, R01 NS088674
Morgan Stanley Foundation Incorporated

    Keywords

    • Anterior cingulate cortex
    • Bipolar depression
    • Combination therapy
    • Dorsolateral prefrontal cortex
    • Dose
    • Electroconvulsive therapy
    • Magnetic seizure therapy
    • Major depressive disorder
    • Medial prefrontal cortex
    • Noninvasive neuromodulation
    • Obsessive-compulsive disorder
    • Post-traumatic stress disorder
    • Supplementary motor area
    • Transcranial direct current therapy
    • Transcranial magnetic stimulation
    • Treatment-resistant depression

    ASJC Scopus subject areas

    • Public Health, Environmental and Occupational Health
    • Behavioral Neuroscience

    Fingerprint

    Dive into the research topics of 'Recent Developments in Noninvasive Neuromodulation for Mood and Anxiety Disorders'. Together they form a unique fingerprint.

    Cite this